Transition Therapeutics Announces Results from Phase 1 AME &amp Renal
TORONTO, March 26, 2015 /PRNewswire/ – Transition Therapeutics Inc. (&quotTransition&quot or the &quotCompany&quot) (NASDAQ: TTHI, TSX:TTH) nowadays announced benefits from two phase 1 clinical studies of neuropsychiatric drug candidate ELND005. These research, an&nbsp…
Read through much more on SYS-CON Media (press release)

Galmed Pharmaceuticals to Current at the Metabolic Leaders&#39 Forum 2015
Dr. Halpern&#39s presentation will be offered on Wednesday, March 25, 2015, at 3:05pm Eastern Time/twelve:05pm Pacific Time, on the subject of &quotTreatment of Non-Alcoholic Fatty Liver Diseases: How early is early?&quot &quotI am enthusiastic to present our pioneering …
Read much more on SYS-CON Media (press release)

1st Ever Uk Survey of Patient Experiences With Hepatic Encephalopathy
A latest survey* commissioned by the British Liver Trust and Liver4Life supported with an unrestricted educational grant from Norgine, exhibits that out of 33 anonymous respondents, more than half had been hospitalised, or observed their loved one particular hospitalised in …
Read far more on SYS-CON Media (press release)

EnglishFrenchGermanItalianPortugueseRussianSpanish